Search results
Results From The WOW.Com Content Network
Studies in patients has shown that most patients experience marked increase in sensory and motor abilities within the first few months of therapy. [1] There are, however, long term studies that have shown that treatment with rituximab can create many immune problems.
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Medicare Part B (medical insurance) may cover Rituxan (rituximab) infusions. This is because medical professionals typically administer the medication in a medical setting on an outpatient basis ...
rituximab + DHAP; that is, rituximab, dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent: relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma R-FCM or FCM-R: rituximab + FCM; that is, rituximab, fludarabine, cyclophosphamide, mitoxantrone: B cell non-Hodgkin lymphoma R-ICE or ICE-R or RICE
The most common cancer among women in the United States is breast cancer (123.7 per 100,000), followed by lung cancer (51.5 per 100,000) and colorectal cancer (33.6 per 100,000), but lung cancer surpasses breast cancer as the leading cause of cancer death among women. [13]
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [160] A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first-line setting, but is FDA-approved in subsequent lines of therapy.
ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.